Shippeo and Elemica Announce Global Partnership to Enhance Supply Chain Orchestration
15.4.2025 16:05:00 CEST | Business Wire | Press release
Shippeo, a global leader in real-time transportation visibility, and Elemica, a global leader in supply chain management and provider of the premier multi-enterprise digital network, announced today a strategic partnership that will enhance supply chain orchestration and visibility for manufacturers worldwide. By integrating Shippeo’s best-in-class transportation visibility solutions with Elemica’s end-to-end supply chain execution capabilities, this partnership offers unparalleled value for complex supply chains, delivering superior automation, decision intelligence, and customer experience.
Delivering Unmatched End-to-End Supply Chain Orchestration and Visibility
Through this alliance, customers will gain access to an integrated solution connecting market-leading shipment tracking powered by Shippeo’s Real-Time Transportation Visibility (RTTV) platform with Elemica’s multi-enterprise network and transportation management systems (TMS) resulting in frictionless logistics workflows with end-to-end tracking and execution.
Additionally, the partnership will unlock new data-driven insights and predictive AI-enabled intelligence helping businesses optimize logistics efficiency, anticipate disruptions, and enhance overall supply chain resilience.
The unmatched combination of inbound and outbound, multi-modal transportation management and execution with multi-modal logistics tracking across ocean, road, parcel, air, and rail, offers complete transparency into shipments, ensuring proactive and efficient management of logistics operations. Moreover, sustainability remains a core focus, as the collaboration enables businesses to optimize routing decisions and track CO₂ emissions, supporting corporate environmental objectives and sustainability initiatives.
“We believe that end-to-end execution and visibility is the foundation of a truly intelligent supply chain,” said Lucien Besse, COO & Co-Founder of Shippeo. “Our partnership with Elemica represents a transformative step forward for businesses seeking to optimize their operations with high-quality, real-time data and predictive insights. Together, we are not just integrating technology—we are revolutionizing how companies orchestrate their supply chains for maximum efficiency, resilience, and sustainability.”
“Elemica has been enabling transparent, efficient & responsive supply chains for critical manufacturing industries for over 25 years,” said Paul Carreiro, CEO at Elemica. “The innovation and partnership with Shippeo continues to create value for our customers, and we’re thrilled to add this level of powerful intelligence to the Elemica Multi-Enterprise Network.”
A Shared Vision for the Future of Supply Chain Innovation
Shippeo and Elemica are united by a vision of fully connected, intelligent, and responsive supply chains. By leveraging Elemica’s expertise in digital supply chain execution and Shippeo’s real-time transportation visibility, businesses can break down information and workflow silos, allowing them to proactively manage disruptions, improve OTIF rates, and continually improve customer service metrics.
This partnership also reinforces a commitment to customer-centric innovation, ensuring that users benefit from automated workflows, real-time tracking, and actionable insights with minimal complexity. The result is an agile and responsive supply chain that adapts to disruptions, strengthens carrier and partner relationships, and drives measurable business growth.
About Shippeo
Shippeo is a global leader in real-time transportation visibility, providing businesses with high-quality, predictive insights and accurate ETAs. Shippeo’s platform connects with thousands of carriers, offering a unified view of shipments across all transport modes. By leveraging AI-driven analytics, Shippeo helps companies optimize supply chain performance and enhance customer satisfaction.
About Elemica
Elemica is a leading provider of Digital Supply Chain Management solutions and the premier multi-enterprise collaboration network for global process manufacturing industries. Its portfolio of SaaS-based, network-powered digitization, execution and visibility solutions automate critical information flows, enable multi-channel data strategies, and improve end-to-end supply chain performance. Elemica solutions connect many of the world’s largest manufacturers to their direct material suppliers, logistics service providers and end customers, helping them realize the promise of, and return on, their investments in supply chain digitization. www.elemica.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415219247/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom